Anti-MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 disease.

Autor: See J; Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia., Fairley JL; Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia.; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia., Yeo AL; Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia.; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia., Ojaimi S; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.; Monash Pathology, Monash Health, Melbourne, Victoria, Australia., Morand EF; Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia.; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
Jazyk: angličtina
Zdroj: Internal medicine journal [Intern Med J] 2024 Nov 11. Date of Electronic Publication: 2024 Nov 11.
DOI: 10.1111/imj.16563
Abstrakt: To evaluate experience in a tertiary rheumatology service with melanoma differentiation-association-protein-5 (MDA5) disease and testing, patients with positive autoantibody results were reviewed for the presence of clinical disease. Anti-MDA5 positivity was detected in 2% of myositis-specific antibody tests. Of these, 29% did not have features consistent with anti-MDA5 disease. However, when present, MDA5 disease is severe with a high mortality.
(© 2024 Royal Australasian College of Physicians.)
Databáze: MEDLINE
Externí odkaz: